Announcements
Lipomedix Pharmaceuticals Ltd. completed LIPORAD-2018 (NCT03823989), a multi-center, open-label, single-arm, prospective study, in patients requiring RT for metastatic disease or for an inoperable primary tumor with no definitive curative treatment option. The clinical study report (CSR) was released (January 2022).
May 2021: The European Patent Office has granted Lipomedix patent (#3270898) entitled "Methods for the Treatment of Bladder Cancer".
March 2021: The Japanese Patent Office has granted Lipomedix patent (#6859275) entitled "Methods for the Treatment of Bladder Cancer".
Lipomedix Pharmaceuticals Ltd. received the Israeli Ministry of Health clearance to launch a Phase 1b clinical trial testing the safety, tolerability and efficacy of Promitil® delivered in combination with the FOLFOX chemotherapy containing two cytotoxic drugs, a fluopyrimidine (5FU) and oxaliplatin for the treatment of advanced gastrointestinal cancers. The study (Promifox) is conducted by investigator at Shaare Zedek Medical Center, Israel (January 2021).
November 2020: Lipomedix Pharmaceuticals has been awarded the Seal of Excellence for the project " A unique ‘smart’ nanomedicine for a safer and more effective chemo-radiotherapy" submitted under the Horizon 2020’s SME Instrument call H2020-EIC-SMEInst-2018-2020 (H2020-EIC-SMEInst-2018-2020-3) in the area of EIC-SMEInst-2018-2020.
August 2020: The European Patent Office has granted Lipomedix patent (# 3151863) entitled "Combination Therapy Comprising A Liposomal Prodrug of Mitomycin C and Radiotherapy"
April 2020: The USPTO has granted Lipomedix patent (#10617672) entitled " Liposome Composition Co-Encapsulating Doxorubicin and A Prodrug of Mitomycin C".
Lipomedix Pharmaceuticals has been awarded the SME Horizon 2020 Phase 1 grant for the project: Promitil® - a new ‘smart’ nanomedicine for cancer chemo-radiotherapy. (July 1, 2019).
Lipomedix Pharmaceuticals Ltd. announces the FDA clearance of its IND application to launch a randomized Phase 2b clinical trial of Promitil for the treatment of patients with previously treated metastatic colorectal cancer (Oct 2018).
Lipomedix Pharmaceuticals Ltd. announces the Israeli Ministry of Health clearance to launch a Phase 1b clinical trial of Promitil in combination with external beam radiotherapy in patients with advanced cancer requiring palliative radiotherapy for inoperable primary tumors or metastatic disease. The study (Liporad-18) will be launched soon and conducted by investigators in two Medical Centers in Israel (Nov 2018).
September 2018: Lipomedix received the approval of a new USPT Patent Application (#10,080,807) for the combined use of Promitil with other chemotherapy entitled "Combination Chemotherapy Comprising a Liposomal Prodrug of Mitomycin C".
April 2018: Lipomedix received the approval of a new USPT Patent Application (#9937261) for the combined use of Promitil with Radiotherapy entitled “Combination Therapy Comprising a Liposomal Prodrug of Mitomycin C and Radiotherapy”.
July-2016: News release from UNC-Chapel Hill Cancer Center on a joint paper with Lipomedix on animal studies with Promitil and radiotherapy (http://unclineberger.org/news/wang-radiation)
May 2016: Lipomedix received a 2 million NIS grant from the Israel Chief Scientist Office for the funding of the project “Development of Promitil a pegylated liposomal MMC- prodrug”.
Presentations
Poster entitled "Pegylated liposomal mitomycin C lipidic prodrug and radiotherapy in advanced cancer patients (pts) – a Phase 1B study" will be presented at the ESTRO 2022 meeting, May 6-10, 2022, Copenhagen, Denmark
Dr. Alberto Gabizon, President and Chief Scientist of Lipomedix, lectured at 12th European and Global Summit for Nanomedicine (CLINAM 2020) in Basel, Switzerland, October 26-28, 2020, on “Pharmacokinetic and Clinical Correlations of Pegylated Liposomal Mitomycin?c Prodrug (Promitil) in Colorectal Cancer Patients” (http://conference.clinam.org/).
Dr. Alberto Gabizon, President and Chief Scientist of Lipomedix, lectured at the Liposome Research Days 2019 Conference in Sapporo, Hokkaido , Japan, September 15-18, 2019 (http://www.knt.co.jp/ec/2019/LRD2019/index.html) on "Promitil® - a lipidic prodrug of mitomycin c in liposomes From bench to bedside"
Poster entitled “Clinical and pharmacokinetic study with a lipidic prodrug of mitomycin-c entrapped in liposomes in metastatic colorectal cancer patients” presented at the American Association for Cancer Research (AACR), annual meeting, Monday Apr 1, 2019 8:00 AM - 12:00 PM, Atlanta, Georgia, US
Poster entitled “Liposome co-encapsulation of doxorubicin and a prodrug of mitomycin-c for pharmacological optimization of combination chemotherapy” presented at the International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) meeting, November 8-9, 2018, Amsterdam, the Netherlands
Poster entitled “A dual drug formulation of pegylated liposomes with co-encapsulated doxorubicin and mitomycin c lipid-based prodrug for chemotherapy of cancer” presented at the Israel Controlled Research Society meeting, October 7-9, 2018, Maalot, Israel
Dr. Alberto Gabizon, CEO and Chief Scientist of Lipomedix, lectured at the 3rd Global Bioequivalence Harmonization Initiative Conference which took place in Amsterdam, April 12-13, 2018 (http://www.eufeps.org/conferences/3rd_GBHI) on "Liposome-based therapeutics: Impact of formulation on pharmacokinetics and pharmacodynamics"
Poster entitled “A Multidrug Formulation of Pegylated Liposomes with Co-Encapsulated Alendronate, Doxorubicin, and Mitomycin-C Lipid–Based Prodrug for Chemo-Immunotherapy of Cancer” presented at the ICRS meeting, September 14-16, 2016, Maalot, Israel
Poster entitled “A Phase 1B Study of Pegylated Liposomal Mitomycin-C Prodrug with or without Capecitabine and Bevacizumab in Third Line Chemotherapy of Colorectal Cancer” presented at the ESMO meeting, October 10-13, 2016, Copenhagen, Denmark
Poster entitled “Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (Promitil®)” presented at Nano Israel Conference, February 22-23, 2016, Tel Aviv University, Israel
Investors
Lipomedix is seeking additional funding from private investors or investment groups for advancing the clinical development of Promitil®, and for further developing its pipeline. Prospective investors are invited to meet with the Company’s management team to discuss an investment in the Company.
